ITMCTR2000003933
Recruiting
Phase 4
A randomized, controlled, single center clinical trial of total glucosides of paeony in the prevention of gout
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Department of Rheumatology and Immunology0 sitesTBD
ConditionsGout
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Gout
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Department of Rheumatology and Immunology
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. The age of 18\-65 years old patients with autonomic activity ability, male patients;
- •2\. The patients who met the diagnostic criteria of gout (American Society of Rheumatology, 1977\); the number of gouty arthritis episodes \>\= 1 in recent half a year;
- •3\. Patients with serum uric acid level \>\= 8\.0 mg / dl (480 µ mol / L);
- •4\. The patients voluntarily participated in the trial and signed the informed consent.
Exclusion Criteria
- •1\. The patients with acute gouty arthritis within one month before enrollment; patients with acute gouty arthritis more than 6 times or single attack duration \>\= 2 weeks in one year before enrollment;
- •2\. Patients with active liver disease or abnormal liver function (ALT and AST are 2 times or more of the upper limit of normal value), and patients with impaired renal function (CR value exceeding the upper limit of normal value);
- •3\. Subjects with white blood cell \< 4\.0 x 10^9 / L, anemia (hemoglobin less than 100g / L), platelet \< 100 x 10^9 / L, or other blood system diseases;
- •4\. Patients with serious heart, lung, central nervous system disease or malignant tumor;
- •5\. Patients with mental illness or mental retardation who can not correctly describe their own feelings or cannot take medicine according to the doctor's advice;
- •6\. Patients with hypertension and diabetes mellitus;
- •7\. Patients with chronic diffuse connective tissue disease;
- •8\. Patients with active peptic ulcer history in recent one year;
- •9\. Patients with history of alcoholism, drug abuse or drug abuse in recent one year;
- •10\. Patients who need to use the prohibited drugs prescribed in the protocol during the trial period;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
A randomized, controlled, single-center clinical study of Xiaoyan Decoction in combination with Durvalumab in the treatment of unresectable advanced NSCLC after radiotherapy and chemotherapylung cancerITMCTR2100004486The First Teaching Hospital of Tianjin University of TCM
Completed
Phase 4
A clinical trial to study the safety and efficacy of Peanut Safe SyringeCTRI/2016/02/006638MERADAS200
Not yet recruiting
Not Applicable
Clinical trial to compare the cognitive improvement effects of electroacupuncture and computerized cognitive rehabilitation for mild cognitive impairmentKCT0008861Dongshin University64
Not yet recruiting
Phase 1
A single center, randomized controlled trial on the treatment of elderly patients with acute myeloid leukemia by attack and reinforcement combined with demethylatioITMCTR2000003828Yueyang integrated traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of traditional Chinese Medicine
Not yet recruiting
Phase 1
Randomized, controlled and single center clinical trial of Jifafang in the treatment of acute exacerbation of chronic obstructive pulmonary diseaseacute exacerbation of chronic obstructive pulmonary diseaseITMCTR2200005789GuiZhou University of traditiongal Chinese Medicine